Top

Published in:

01-01-2012 | Letter to the Editor

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

Authors: Christina Justenhoven, Ofure Obazee, Stefan Winter, Fergus J. Couch, Janet E. Olson, Per Hall, Ulf Hannelius, Jingmei Li, Keith Humphreys, Gianluca Severi, Graham Giles, Melissa Southey, Laura Baglietto, Peter A. Fasching, Matthias W. Beckmann, Arif B. Ekici, Ute Hamann, Christian Baisch, Volker Harth, Sylvia Rabstein, Anne Lotz, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Hiltrud Brauch

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Excerpt

To the Editor, …

Key TJ, Allen NE, Spencer EA, Travis RC (2002) The effect of diet on risk of cancer. Lancet 360:861–868PubMedCrossRef

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587PubMedCrossRef

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692PubMedCrossRef

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Writing group for the Women’s Health Initiative investigators risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314PubMedCrossRef

Jordan VC, Ford LG (2011) Paradoxical clinical effect of estrogen on breast cancer risk: a “New” biology of estrogen-induced apoptosis. Cancer Prev Res 4:633–637CrossRef

Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11:206PubMedCrossRef

Pasqualini JR (2007) Progestins and breast cancer. Gynecol Endocrinol 23(Suppl 1):32–41PubMedCrossRef

Wiebe JP (2006) Progesterone metabolites in breast cancer. Endocr Relat Cancer 13:717–738PubMedCrossRef

10.

Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH (2001) Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin 22:148–154PubMed

11.

Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM (2006) Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomark Prev 15:551–558CrossRef

12.

Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–169PubMedCrossRef

13.

Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174–183PubMedCrossRef

14.

De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598PubMed

15.

Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R, Morgan GJ (2000) Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10:605–615PubMedCrossRef

16.

Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113PubMedCrossRef

17.

Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Bruning T, Winter S, Ko YD, Brauch H (2009) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 115:391–396PubMedCrossRef

18.

Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Bruning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H (2008) The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 111:171–177PubMedCrossRef

19.

Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S, Pierl C, Fischer HP, Baisch C, Justenhoven C, Ranft U, Bruning T (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20:699–711PubMedCrossRef

20.

Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 6:R437–R449PubMedCrossRef

21.

Olson JE, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Ingle JN, Wu Y, Couch F, Sellers TA, Weinshilboum RM, Vachon CM (2007) A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomark Prev 16:623–625CrossRef

22.

Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156:69–70PubMed

23.

Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA (2008) Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 134:873–882PubMedCrossRef

24.

Key TJ (2011) Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 76:812–815PubMedCrossRef

25.

Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877–880PubMedCrossRef

Title: The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant
Authors: Christina Justenhoven
Ofure Obazee
Stefan Winter
Fergus J. Couch
Janet E. Olson
Per Hall
Ulf Hannelius
Jingmei Li
Keith Humphreys
Gianluca Severi
Graham Giles
Melissa Southey
Laura Baglietto
Peter A. Fasching
Matthias W. Beckmann
Arif B. Ekici
Ute Hamann
Christian Baisch
Volker Harth
Sylvia Rabstein
Anne Lotz
Beate Pesch
Thomas Brüning
Yon-Dschun Ko
Hiltrud Brauch
Publication date: 01-01-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1827-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients

Erratum to: The BRCA2 c.9004G>A (E3002K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent

A randomized clinical trial comparing advanced pneumatic truncal, chest, and arm treatment to arm treatment only in self-care of arm lymphedema

Erratum to: HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies

The vitamin D pathway and mammographic breast density among postmenopausal women

Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer